- The collaboration focuses on gastroenterology, dermatology, and neurology.
- Mayo Clinic provides clinical insights and genomic data.
- Merck integrates AI and machine learning for drug discovery.
Collaboration Overview
Merck and Mayo Clinic have announced a strategic collaboration to enhance drug discovery and development using artificial intelligence (AI) and machine learning (ML). This partnership integrates Mayo Clinic's clinical insights and genomic data with Merck's AI capabilities.
Data Integration
The collaboration leverages the Mayo Clinic Platform, which combines data from Mayo Clinic's U.S. and international partners. This includes de-identified clinical and multimodal datasets, registries, and biorepositories, providing Merck with access to advanced AI tools and analytics.
Focus Areas
The initial focus is on high-need therapeutic areas, specifically gastroenterology, dermatology, and neurology. The aim is to develop more effective and tailored therapies for conditions such as inflammatory bowel disease, atopic dermatitis, and multiple sclerosis.
Strategic Goals
By integrating high-quality clinical data and AI-enabled insights, the collaboration seeks to improve target identification and increase the probability of success in drug development programs. This partnership marks Mayo Clinic's first large-scale collaboration with a global biopharmaceutical company.
